News

Ideas That Generate Results

The new report by RNCOS by the name of “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022,” predicts that the Immuno-oncology market has experienced tremendous growth in recent years and is estimated to cross the value of US$ 100 Billion by 2022. Since the introduction of the first monoclonal antibody Rituxan in the US in 1997, the market has grown immensely with respect to the frequency of use and commercialization prospects. This, in turn, has attracted a large number of major drug manufacturers as well as many venture capitalists to invest into this swiftly growing segment. All these factors point towards a stupendous growth in immuno-oncology market in the future.
 
Till date, immuno-oncolgy therapies approved for use in clinical practices comprise of vaccines, cytokines, tumor-directed monoclonal antibodies, and immune checkpoint inhibitors. Additional types of Immuno-oncolgy therapies, such as immune cell therapy and immune-modulatory molecules are in advanced research phases and possess a huge growth potential.
 
This report is spread in 170 pages and provides an in-depth research and rational analysis of the current status and future prospect of the Immuno-oncology market. The report analyzes the market for major immuno-oncology drugs in detail. The report also provides an insight into the key immuno-oncology drugs that are currently in pipeline. A brief analysis is being done on the basis of types of immuno-oncology drugs and clinical phases.
                                                                                        
Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over Immuno-oncology market have been provided. At the end, major players of Immuno-oncology market have been discussed. A brief business overview of every player has been provided alongwith their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM887.htm
 
Check Related REPORTS on: http://www.rncos.com/biotech.htm